(Reuters) -Pfizer Inc said on Tuesday its vaccine to prevent infections from the clostridioides difficile bacteria failed to meet the main goal of a late-stage study.
The vaccine only showed an efficacy of 31% after the third dose and 28.6% following the second dose in the study, whose main goal was preventing infections.
But Pfizer said it would evaluate next steps as the trial showed the vaccine helped reduce the severity of infections.
Clostridioides difficile infection is a serious infection associated with diarrhea that may progress to severe and debilitating illness and even result in death. The U.S. Centers for Disease Control and Prevention has classified it as an urgent public health threat.
(Reporting by Manas Mishra in Bengaluru; Editing by Aditya Soni)
